Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

I am initiating a 'sell' rating on Hims & Hers Health, with a fair value of $35 per share, due to imminent growth risks.

Shares of Hims & Hers plunged over 30% after Wegovy maker Novo Nordisk abruptly ended their partnership on Monday, accusing ...

Deepseek AI’s scare kicked off the year, rattling faith in the “Magnificent Seven” and the broader tech space. 💵💰Don't miss ...

As voters head to the polls, the democratic socialist candidate appears to be neck-and-neck with Andrew Cuomo. That has many ...

Stock markets have rallied and oil prices fell after U.S. President Donald Trump announced what appears to be a shaky ...

The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces a new, interactive digital ...